- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03671330
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis.
This is a Phase II randomized, double-blind, placebo-controlled study involving premenopausal and postmenopausal Chinese women plus an open-label single arm of pharmacokinetic cohort of LEE011 in combination with Letrozole in Chinese postmenopausal women with HR+, HER2- negative advanced breast cancer.
Three cohorts of patients will be enrolled: PK cohort, premenopausal cohort, and postmenopausal cohort.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100044
- Novartis Investigative Site
-
Beijing, China, 100036
- Novartis Investigative Site
-
Fuzhou, China, 350001
- Novartis Investigative Site
-
Qingdao, China, 266000
- Novartis Investigative Site
-
Shanghai, China, 200032
- Novartis Investigative Site
-
Shanghai, China, 200025
- Novartis Investigative Site
-
Tianjin, China, 300480
- Novartis Investigative Site
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Novartis Investigative Site
-
-
Chongqing
-
Chongqing, Chongqing, China, 404100
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Novartis Investigative Site
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Novartis Investigative Site
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Novartis Investigative Site
-
Suzhou, Jiangsu, China, 215004
- Novartis Investigative Site
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330009
- Novartis Investigative Site
-
-
Jilin
-
Chang Chun, Jilin, China, 130021
- Novartis Investigative Site
-
-
Liaoning
-
Shengyang, Liaoning, China, 110016
- Novartis Investigative Site
-
Shengyang, Liaoning, China, 110042
- Novartis Investigative Site
-
-
Shanxi
-
Xian, Shanxi, China, 710061
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
-
Yunnan
-
Kunming, Yunnan, China, 650106
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Novartis Investigative Site
-
Hangzhou, Zhejiang, China, 310006
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor (ER) positive and/or progesterone receptor positive breast cancer by local laboratory (based on most recently analyzed biopsy).
- Patient has HER2-negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.
Patient must have either:
- Measurable disease, i.e., at least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is a clear sign of progression since the irradiation). OR
- If no measurable disease is present, then at least 1 predominantly lytic bone lesion must be present (patients with no measurable disease and only 1 predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).
- Patient has ECOG performance status 0 or 1.
For premenopausal cohort:
- Patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent and has signed informed consent before any trial related activities are conducted and according to local guidelines.
- Confirmed negative serum pregnancy test before starting study treatment or patient has had a hysterectomy.
- Patient has advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer not amenable to curative therapy (e.g.
surgery and/or radiotherapy).
- Patients who received ≤ 14 days of a NSAI (letrozole or anastrozole) with or without goserelin or goserelin ≤ 28 days for advanced breast cancer prior to randomization are eligible. Patients must continue treatment with the same hormonal agent + goserelin during the study. No treatment interruption is required for these patients prior to randomization.
- Patients who have received up to 1 line of chemotherapy for advanced breast cancer and have been discontinued 28 days before randomization are eligible.
For postmenopausal cohort:
- Patient is an adult, female ≥ 18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines.
- Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Exclusion Criteria:
- Patient who has received a prior CDK4/6 inhibitor.
- Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment
- Patient with CNS metastases.
- Patient who has not had resolution of clinical and laboratory acute toxicities related to prior anti-cancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grade ≤1.
- Patient has a known history of Human immunodeficiency Virus (HIV) infection (testing not mandatory).
- Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- Patient is currently receiving any of the substances as defined in the protocol that cannot be discontinued 7 days prior to the start of the treatment:
For premenopausal cohort:
- Pregnant or nursing (lactating) women.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment and for 21 days after stopping study medication.
Note: Use of oral (estrogen and progesterone), transdermal, injected or implanted hormonal methods of contraception as well as hormonal replacement therapy is not allowed in this study.
For postmenopausal cohort:
- Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer.
Note: Patients who received neo (adjuvant) therapy for breast cancer are eligible. If the prior neo (adjuvant) therapy included letrozole or anastrozole, the disease free interval must be greater than 12 months from the completion of treatment until randomization.
- Patients who received ≤ 14 days of letrozole or anastrozole for advanced disease prior to randomization are eligible.
Other protocol-defined inclusion/exclusion may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ribociclib
Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm. Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent. It is the investigators choice for NSAI based on patient's past medical history. Postmenopausal experimental arm: Letrozole + Ribociclib PK Cohort: Open-label ribociclib + Letrozole treatment combination. For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent |
Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Other Names:
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption). Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history. For postmenopausal and PK cohorts, all patients will be on Letrozole.
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
|
Placebo Comparator: Ribociclib Placebo
Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm. Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent. It is the investigators choice for NSAI based on patient's past medical history. Postmenopausal control arm: Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent |
Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Other Names:
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption). Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history. For postmenopausal and PK cohorts, all patients will be on Letrozole.
Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
Other Names:
Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progressive free survival (PFS) based on local assessment by RECIST 1.1 guideline
Time Frame: The primary analysis will be conducted for pre and postmenopausal cohorts separately when approximately 100 PFS events have been observed in pre- and postmenopausal cohorts (approximately 23 months).
|
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.
If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.
|
The primary analysis will be conducted for pre and postmenopausal cohorts separately when approximately 100 PFS events have been observed in pre- and postmenopausal cohorts (approximately 23 months).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmaconinetic (PK) parameter: Cmax
Time Frame: 10 months
|
For PK cohort only.
Maximum (peak) concentration of drug in plasma.
|
10 months
|
PK parameter: Tmax
Time Frame: 10 months
|
For PK cohort only.
Time to reach maximum plasma concentration.
|
10 months
|
PK parameter: AUC024h
Time Frame: 10 months
|
For PK cohort only.
Area under the plasma concentration curve versus time.
|
10 months
|
Overall Survival (OS)
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Overall Survival is defined as the time from date of randomization to date of death due to any cause.
|
50 months
|
Overall response rate (ORR)
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Overall response rate is defined as the proportion of patients with best overall response (BOR) of CR or PR according to RECIST 1.1
|
50 months
|
Clinical Benefit Rate (CBR)
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Clinical Benefit Rate is defined as percentage of patients with CR, PR per RECIST or SD lasting 24 weeks or longer, per RECIST 1.1
|
50 months
|
Time To Response (TTR)
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Time to response is defined as the time from the date of randomization to the first documented response either CR or PR, which must be subsequently confirmed (although date of initial response is used, not date of confirmation) according to RECIST 1.1.
|
50 months
|
Duration of Response (DoR)
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Duration of Response applies only to patients whose best overall response is CR or PR according to RECIST1.1.
|
50 months
|
Time to deterioration of ECOG performance status from baseline
Time Frame: 50 months
|
For pre- and postmenopausal cohorts only.
Time to definitive deterioration in ECOG performance status is defined as the time from the date of randomization to the date when ECOG performance status has definitively deteriorated by at least 1 category compared with baseline.
|
50 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Goserelin
- Anastrozole
Other Study ID Numbers
- CLEE011A2206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Ribociclib
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Fox Chase Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Nader SanaiNovartis; Barrow Neurological Institute; Ivy Brain Tumor CenterActive, not recruitingGlioblastoma Multiforme | MeningiomaUnited States
-
Assaf-Harofeh Medical CenterUnknownSoft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed TypeIsrael
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Hadassah Medical OrganizationUnknownSoft Tissue Sarcoma | LiposarcomaIsrael
-
Children's Hospital Medical Center, CincinnatiNovartisTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade GliomaUnited States